- 1.
Hansen KS. Koronaviruset kjenner ingen grenser. Tidsskr Nor Legeforen 2020; 140. doi: 10.4045/tidsskr.20.0214. [CrossRef]
- 2.
Ihle-Hansen H, Berge T, Tveita A et al. Covid-19: Symptomer, forløp og bruk av kliniske skåringsverktøy hos de 42 første pasientene innlagt på et norsk lokalsykehus. Tidsskr Nor Legeforen 2020; 140. doi: 10.4045/tidsskr.20.0301. [PubMed][CrossRef]
- 3.
Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020; 135: 2033–40. [PubMed][CrossRef]
- 4.
Tveit A, Hestenes S, Sporastøyl ER et al. Lungeembolisme ved covid-19. Tidsskr Nor Legeforen 2020; 140. doi: 10.4045/tidsskr.20.0366. [CrossRef]
- 5.
Lodigiani C, Iapichino G, Carenzo L et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 2020; 191: 9–14. [PubMed][CrossRef]
- 6.
Mosevoll KA, Johansen S, Wendelbo Ø et al. Cytokines, adhesion molecules, and matrix metalloproteases as predisposing, diagnostic, and prognostic factors in venous thrombosis. Front Med 2018; 5: 147. [PubMed][CrossRef]
- 7.
Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013; 13: 34–45. [PubMed][CrossRef]
- 8.
Ackermann M, Verleden SE, Kuehnel M et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020; 382: NEJMoa2015432. [PubMed][CrossRef]
- 9.
Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020; 368: 473–4. [PubMed][CrossRef]
- 10.
Varga Z, Flammer AJ, Steiger P et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417–8. [PubMed][CrossRef]
- 11.
Lu R, Zhao X, Li J et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395: 565–74. [PubMed][CrossRef]
- 12.
Lighter J, Phillips M, Hochman S et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis 2020; 70: ciaa415. [PubMed][CrossRef]
- 13.
Cheng Y, Luo R, Wang K et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020; 97: 829–38. [PubMed][CrossRef]
- 14.
Llitjos JF, Leclerc M, Chochois C et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020; 18: jth.14869. [PubMed][CrossRef]
- 15.
Klok FA, Kruip MJHA, van der Meer NJM et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res 2020; 191: 148–50. [PubMed][CrossRef]
- 16.
Middeldorp S, Coppens M, van Haaps TF et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18: jth.14888. [PubMed][CrossRef]
- 17.
Wichmann D, Sperhake JP, Lütgehetmann M et al. Autopsy findings and venous thromboembolism in patients with COVID-19: A prospective cohort study. Ann Intern Med 2020; 172: M20-2003. [PubMed][CrossRef]
- 18.
Helms J, Tacquard C, Severac F et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46: 1–20. [PubMed][CrossRef]
- 19.
Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–62. [PubMed][CrossRef]
- 20.
Tang N, Bai H, Chen X et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18: 1094–9. [PubMed][CrossRef]
- 21.
Thachil J, Tang N, Gando S et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020; 18: 1023–6. [PubMed][CrossRef]
- 22.
Tang N, Li D, Wang X et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18: 844–7. [PubMed][CrossRef]
- 23.
Bikdeli B, Madhavan MV, Jimenez D et al. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020; 16: 2950–73. [PubMed][CrossRef]
- 24.
Tveiten H, Aukrust P, Lehne G et al. Hemofagocytisk lymfohistiocytose ved covid-19? Tidsskr Nor Legeforen 2020; 140. doi: 10.4045/tidsskr.20.0240. [PubMed][CrossRef]
- 25.
Barnes GD, Burnett A, Allen A et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis 2020; 50: 72–81. [PubMed][CrossRef]
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.